AI Meets Game Theory: How Language Models Perform in Human-Like Social Scenarios
more
Stories from Tübingen
- Language:
- Media:
- Period:
- Period:Total
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
moreAcousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...
moreCustomCells strengthens its commitment in eAviation
moreHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
moreAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
more
Energy at its best: German battery pioneer CustomCells unveils new brand identity
morePress Release: Instone sells 105 predominantly subsidized apartments in the "Neckar.Au Viertel" to the city of Rottenburg am Neckar
One documentmoreHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
moreHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
moreHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
moreProject TwinTrace: Customcells works together with partners on a smart battery factory
more
Customcells strengthens sustainable battery industry ‘Made in Germany’
moreGerman battery pioneer closes Series A financing round: 60 million euros for Customcells
moreCUSTOMCELLS publishes future theses for Germany's battery industry
moreCellforce Group lays foundation for modern, sustainable battery production in Europe
more10 years of CUSTOMCELLS: Battery cell specialist ready for the next phase of growth
moreBattery innovator's new CEO / Dirk Abendroth joins CUSTOMCELLS' Board of Management
more
The year of battery cell technology: CUSTOMCELLS expects massive growth in 2022
moreCUSTOMCELLS brings three new shareholders on board following funding round
moreCellforce Group GmbH: Joint Venture between Porsche and CUSTOMCELLS
moreTechnische Universität München
A molecular map for the plant sciences
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/ High resolution images: https://mediatum.ub.tum.de/1540641 NEWS RELEASE First comprehensive map of the proteome of the model plant Arabidopsis thaliana A molecular map for the plant sciences Plants are essential for ...
moreTechnische Universität München
The GERDA-Collaboration: Major steps forward in understanding neutrino properties
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: http://www.tum.de/nc/die-tum/aktuelles/pressemitteilungen/details/35672/ High resolution images: https://mediatum.ub.tum.de/1518985 NEWS RELEASE Closing in on elusive particles Major steps forward in understanding ...
more
1